On May 7, 2022 Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics reported that it will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference (Press release, Exacis Biotherapeutics, MAY 7, 2022, View Source [SID1234613846]). The panel, "Autologous vs Allogeneic," is part of the Gene Modified Cell Therapy track for conference attendees. Exacis is a cell therapy company using mRNA to reprogram somatic cells to iPSCs and then using a proprietary mRNA based gene editing platform to engineer the cells before differentiation into immune effector (T and NK) cells for cancer applications. Dr. Fiore will share his knowledge of the research and developments in the rapidly growing cell therapy field.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The currently approved autologous cell therapies are making a big difference for patients, although they are limited in their availability due to multiple factors. Allogeneic therapies hold promise to overcome these accessibility barriers," said Dr. Fiore. "Exacis and others are working to develop lower cost, off-the-shelf cell therapies in order to allow many more patients to benefit from these lifesaving treatments."

The panel will take place at 12:20 pm GMT on Wednesday, May 25.

The Advanced Therapies Conference will be held May 24-25, 2022, in London. Meeting attendees will explore important topics in the Advanced Therapy Medicinal Products (ATMP) space and the conference will showcase the latest technologies and advancements in the industry. The event will bring together 1,500 attendees from across the ATMP industry from pharma, biotech, research, regulatory bodies, HTAs investment and start-ups. The agenda includes 8 focused topic tracks, 300 speakers, and 100 sponsors and exhibitors.

On May 6, 2022 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") reported a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022 (Press release, Aurinia Pharmaceuticals, MAY 6, 2022, View Source [SID1234613780]). The new numbers for interested participants to dial in are: (866) 682-6100 / (862) 298-0702 (Toll-free U.S. & Canada).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio webcast can also be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

On May 6, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May (Press release, Ambrx, MAY 6, 2022, View Source [SID1234613801]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM Pacific Time / 3:00 PM Eastern Time.

H.C. Wainwright Global Investment Conference. Dr. Tian will conduct a pre-recorded presentation that will be available on-demand on Tuesday, May 24 at 4:00 AM Pacific Time / 7:00 AM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company’s website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.

On May 6, 2022 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will present at the following conferences (Press release, BioCryst Pharmaceuticals, MAY 6, 2022, View Source [SID1234613781]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at 11:00 a.m. ET.

The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 18, 2022 at 1:35 p.m. ET.

The H.C. Wainwright Global Investment Conference – pre-recorded fireside chat available beginning Tuesday, May 24, 2022 at 7:00 a.m. ET.
Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

On May 6, 2022 InterVenn Biosciences, the leader in applied glycoproteomics, reported that it will present new clinical data detailing the success of its novel approach to liquid biopsy testing in multiple cancer indications at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting (Press release, InterVenn Biosciences, MAY 6, 2022, View Source [SID1234613802]). The meeting will take place from June 3 to June 7 at McCormick Place in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

InterVenn will present two posters and five online publications highlighting data that demonstrate clinically relevant applications of its glycoproteomics-based biomarker signatures in a variety of cancers, including malignant melanoma, ovarian cancer, colorectal cancer, non-small-cell lung carcinoma, and bone and soft tissue sarcoma.

"We look forward to sharing our data at ASCO (Free ASCO Whitepaper) 2022 further validating the power of InterVenn’s pioneering glycoproteomic biomarker signatures to transform clinical care in cancer," said InterVenn CEO Aldo Carrascoso. "As a mission-driven company, InterVenn is building a robust pipeline of accessible, clinically validated and powerful tests, with the aim of detecting cancer earlier, treating it more effectively, and saving lives."

The InterVenn approach addresses many of the common challenges associated with liquid biopsy analysis by industrializing the process of glycoproteomics-based blood testing at high accuracy with fast turnaround times. Unlike other non-invasive methods, it does not depend on detecting material shed by tumors, and therefore allows the detection of very early-stage, potentially curable tumors that are commonly missed by other technologies. It also requires a significantly lower blood sample volume than most other analytical platforms.

InterVenn Presentations at ASCO (Free ASCO Whitepaper) 2022

Poster Presentations:

Title: "Serum glycoproteomic signatures predict overall survival in bone and soft tissue sarcoma patients treated with immune checkpoint inhibitor therapy"
Presenter: D. Serie, C. Pickering, R. Rice, M. Wong, H. Huang, M. Kansara, DM. Thomas, and K. Lindpaintner

Title: "Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment benefit in metastatic malignant melanoma"
Presenter: A. Mitchell, C. Pickering, G. Xu, K. Vigal, B. Axenfeld, R. Rice, X. Cong, D. Frederick, W. A. Michaud, G. Boland, D. Serie, and K. Lindpaintner

Online Publications:

Title: "Glycoproteomics as a powerful liquid biopsy based screening tool for NSCLC"
Author: C. Pickering, G. Xu, R. Rice, A. Castellanos, R. Bhadra, L. Brcic, J. Lindenmann, F.M. Smolle-Juettner, K. Lindpaintner, D. Serie, and A. Mitchell

Title: "Clinicians’ perspectives on use of immune checkpoint inhibitors and related biomarkers for solid tumors"
Author: K. Moser, M. Soto, D. Geba, P. Allen, and K. Lindpaintner

Title: "Identifying potential glycoproteomic biomarkers for diagnosis of colorectal cancer"
Author: K. Desai, G. Xu, R. Rice, A. Castellanos, D. Serie, A. Mitchell, and K. Lindpaintner

Title: "Liquid-biopsy derived glycoproteomic profiling as a novel means for non-invasive diagnosis of ovarian cancer"
Author: C. Pickering, P. Aiyetan, G. Xu, R. Rice, P. Ramachandran, K. Moser, D. Serie, and K. Lindpaintner

Title: "Predicting Breast Cancer in Women using Liquid Biopsy-Derived Glycoproteomic Marker"
Author: A. Mitchell, A. Srinivasan, G. Xu, R. Rice, A. Castellanos, R. Bhadra, D. Serie, X. Cong, and K. Lindpaintner